Probiotic did not prevent diarrhea among patients taking antibiotics
Click Here to Manage Email Alerts
Treatment with Saccharomyces boulardii did not prevent the onset of antibiotic- or Clostridium difficile-associated diarrhea in hospitalized patients receiving antibiotics in a recent study.
In a single-center, randomized, double blind, placebo-controlled, parallel-group trial, 275 patients aged 79.2 years±9.8 years began a regimen less than 48 hours after starting antibiotic therapy of either a placebo (n=134) or probiotic S. boulardii (n=141). Participants continued to receive the treatment for 7 days following antibiotic withdrawal, with 12 weeks of follow-up.
Follow-up was completed by 204 patients aged 78.4 years±10 years, including 106 in the probiotic group and 98 in the placebo group. In the probiotic group, 15.1% (16 patients) developed antibiotic-associated diarrhea (AAD), compared with 13.3% (13 patients) in the placebo group (OR=1.16; 95% CI, 0.53-2.56). The condition developed a median of 26 days after enrollment, manifesting after 16 days in the placebo group and 36 days in the probiotic group (P=.17). The probiotic group reported significantly more smoking and alcohol consumption than the placebo group (P=.05), but the difference in AAD development across the two groups was not found to be statistically significant after adjusting for this difference (adjusted OR=1.00; 95% CI, 0.44-2.27).
Three probiotic patients and two placebo patients developed C. difficile-associated diarrhea. The difference in occurrence between the groups was not found to be statistically significant (OR=1.40; 95% CI, 0.23-8.55).
Across both groups, 71 participants died before follow-up was completed (36 in the placebo group; 35 in the probiotic group), and researchers observed no significant difference in the mortality rates between groups (P=.60).
“In this study, S. boulardii was shown to be unable to prevent the development of AAD, at least in a context with a low incidence of … cases,” researchers wrote.